Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a large extent by new biotech listings. “Biotechnology is today the fastest-growing IPO market segment,” says…
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies…
2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating biotech and biotech-related firms, mostly originating from mainland…
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar 2020 for the Exchange and…
Andrew Hexter, VP and GM of Gilead Asia 5 (Hong Kong, Singapore, South Korea, Taiwan and Malaysia), shares the highlights of his past three years leading the diverse region, the…
Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong…
Dr Albert Yu, chairman of the Hong Kong Biotechnology Organization (HKBIO) gives his expert insights into the crucial importance of diagnostics in countering the COVID-19 pandemic, how Hong Kong’s positioning…
Dr Joseph Tam is indisputably one of the pioneers of Hong Kong’s biotech industry, having returned to Hong Kong in 1973 following an illustrious career in the US to bring…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain…
With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the HKEX’s Michael Chan outlined some of the…
Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu Hengrui, are now officially the wealthiest couple in China. Sun, a former high…
Three years after the Hong Kong Stock Exchange (HKEX) introduced reforms to allow and support the listing of pre-profit biotech companies, it has become Asia’s largest, and the world’s second-largest,…
The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the…
See our Cookie Privacy Policy Here